PharmaEngine, Inc. (TPEX:4162)
70.50
-0.60 (-0.84%)
Nov 3, 2025, 1:30 PM CST
PharmaEngine Company Description
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan.
It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells.
The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors.
PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
PharmaEngine, Inc.
| Country | Taiwan |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Hong-Ren Wang |
Contact Details
Address: 10 Minsheng East Road Taipei, 104 Taiwan | |
| Phone | 886 2 2515 8228 |
| Website | pharmaengine.com |
Stock Details
| Ticker Symbol | 4162 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0004162003 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Hong-Ren Wang Ph.D. | President and Chief Executive Officer |
| Chi-Hsing Chang CPA | Vice President of Corporate Development |
| Melody Lin | Director of Human Resources |